Download PDF
Thromb Haemost 2004; 92(04): 707-712
DOI: 10.1160/TH04-05-0293
Theme Issue Article
Schattauer GmbH

Total tissue factor pathway inhibitor is an independent risk factor for symptomatic paediatric venous thromboembolism and stroke

Christine Duering
1   Department of Paediatric Haematology and Oncology, University of Münster, Germany
,
Andrea Kosch
1   Department of Paediatric Haematology and Oncology, University of Münster, Germany
,
Claus Langer
2   Institute of Clinical Chemistry and Institute of Arteriosclerosis Research, University of Münster, Germany
,
Sabine Thedieck
1   Department of Paediatric Haematology and Oncology, University of Münster, Germany
,
Ulrike Nowak-Göttl
1   Department of Paediatric Haematology and Oncology, University of Münster, Germany
› Author AffiliationsFinancial support: This study was supported by an unrestricted grant awarded by the Karl Bröcker Stiftung.
Further Information

Publication History

Received 12 May 2004

Accepted after resubmission 27 July 2004

Publication Date:
06 December 2017 (online)

    Permissions and Reprints

Summary

Tissue factor pathway inhibitor (TFPI) plays an important role in inhibiting tissue factor-induced coagulation by a factor Xadependent pathway of the activated tissue-factor VIIa complex. Decreased values of the latter inhibitor have been recently reported in adult patients with venous thrombosis (VT) or ischaemic stroke (IS). The present case-control study was therefore performed to evaluate whether a decreased TFPI concentration is also involved in paediatric symptomatic thromboembolism (ST). Total TFPI concentrations were measured along with established prothrombotic risk factors six to twelve months after the acute thrombotic onset in 144 Caucasian children aged 0.6 to 18 years (VT: n=80; IS: n=64). The cut-off values defined as age-dependent 10th percentiles were obtained from 244 healthy controls. Median (range) values of TFPI were significantly lower in patients compared with control subjects [50.0(20.0-132.3) ng/ml vs. 59.5(25.4-117.4) ng/ml; p-value < 0.0001]. In addition, 42 of the 144 patients (29.2%) compared with 25 of the 244 controls (10.2%) showed TFPI concentrations below the 10th age-dependent percentiles. Compared to baseline values 78.6% of children with total TFPI Ag < 10th percentiles showed a low response to enoxaparin administration, whereas in children with normal baseline TFPI values 30% show a low TFPI release (p= 0.007). Multivariate analysis adjusted for the presence of established prothrombotic risk factors showed a significantly increased odds ratio (OR) and 95% confidence interval (CI) for patients with ST [OR/CI: 3.8/2.2-6.6; p< 0.0001]. Data shown here give evidence that total TFPI concentrations below the 10th age-dependent percentiles independently increase the risk of ST in Caucasian children 3.8-fold.

Keywords

TFPI - factor V G1691A - lipoprotein (a) - paediatric thromboembolism
 

  • References

  • 1 Andrew M, Vegh P, Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-05.
    PubMedGoogle Scholar
  • 2 Andrew M. Developmental hemostasis: Relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74: 415-25.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Andrew M, David M, Adams M. et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian registry of VTE. Blood 1994; 83: 1251-7.
    PubMedGoogle Scholar
  • 4 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939-43.
    PubMedGoogle Scholar
  • 5 Massicotte MP, Dix D, Monagle P. et al. Central venous catheter related thrombosis in children: Analysis of the Canadian Registry of venous thromboembolic complications. J Pediatr 1998; 133: 770-6.
    CrossrefPubMedGoogle Scholar
  • 6 Monagle P, Adams M, Mahoney M. et al. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Pediatr Res 2000; 47: 763-6.
    CrossrefPubMedGoogle Scholar
  • 7 Van Ommen CH, Heijboer H, Buller HR. et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 2001; 139: 676-81.
    CrossrefPubMedGoogle Scholar
  • 8 Lane A, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95: 1517-26.
    PubMedGoogle Scholar
  • 9 Junker R, Koch HG, Auberger K. et al. Prothrombin G20210A gene mutation and further prothrombotic risk factors in childhood thrombophilia. Arterioscler Thromb Vasc Biol 1999; 19: 2568-72.
    CrossrefPubMedGoogle Scholar
  • 10 Bonduel M, Hepner M, Sciuccati G. et al. Prothrombotic abnormalities in children with venous thromboembolism. J Pediatr Hematol Oncol 2000; 22: 66-72.
    CrossrefPubMedGoogle Scholar
  • 11 Nowak-Göttl U, Junker R, Hartmeier M. et al. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999; 100: 743-8.
    CrossrefPubMedGoogle Scholar
  • 12 Nowak-Göttl U, Sträter R, Heinecke A. et al. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin and methylenetetrahydrofolate reductase are risk factors of ischaemic stroke in childhood. Blood 1999; 94: 3678-82.
    PubMedGoogle Scholar
  • 13 Kenet G, Sadetzki S, Murad H. et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-8.
    CrossrefPubMedGoogle Scholar
  • 14 Bajaj MS, Birktoff JJ, Steer SA. et al. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Sandset PM, Bendz B. Tissue factor pathway inhibitor: clinical deficiency states. Thromb Haemost 1997; 78: 467-70.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Novotny WF, Girard TJ, Miletich JP. et al. Purification and characterisation of the lipo-protein-associated coagulation inhibitor from human plasma. J Biol Chem 1989; 264: 18832-7.
    PubMedGoogle Scholar
  • 17 Llobet D, Falcon L, Mateo J. et al. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia. Thromb Res 1995; 80: 413-8.
    CrossrefPubMedGoogle Scholar
  • 18 Ariëns RAS, Alberio G, Moia M. et al. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost 1999; 81: 203-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Dahm A, van Hylckama AVlieg, Bendz B. et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-92.
    CrossrefPubMedGoogle Scholar
  • 20 Abumiya T, Yamaguchi T, Terasaki T. et al. Decreased plasma tissue factor pathway inhibitor activity in ischemic stroke patients. Thromb Haemost 1995; 74: 1050-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Blann A, Amiral J, Mc CCollum. et al. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral artery disease compared to healthy controls. Atherosclerosis 2000; 152: 29-34.
    CrossrefPubMedGoogle Scholar
  • 22 Weissbach G, Harenberg J, Wendisch J. et al. Tissue factor pathway inhibitor in infants and children. Thromb Res 1994; 73: 441-46.
    CrossrefPubMedGoogle Scholar
  • 23 Tay SP, Cheong SK, Boo NY. Circulating tissue factor, tissue factor pathway inhibitor and D-dimer in umbilical cord blood of normal term neonates and adult plasma. Blood Coagul Fibrinolysis 2003; 14: 125-9.
    CrossrefPubMedGoogle Scholar
  • 24 Hoppensteadt D, Jeske W, Fareed J. et al. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995; 06: S57-S64.
    CrossrefPubMedGoogle Scholar
  • 25 Ariëns RAS, Moia M, Rivolta E. et al. High levels of tissue factor pathway inhibitor in patients with nephrotic proteinuria. Thromb Haemost 1999; 82: 1020-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Falciani M, Gori AM, Fedi S. et al. Elevated tissue factor and tissue factor pathway inhibitor circulation levels in ischaemic heart disease patients. Thromb Haemost 1998; 79: 495-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Leurs PB, van Oerle R, Hamulyak K. et al. Tissue factor pathway inhibitor activity in patients with IDDM. Diabetes 1995; 44: 80-4.
    CrossrefPubMedGoogle Scholar
  • 28 Iversen N, Lindahl AK, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol 1998; 101: 889-95.
    PubMedGoogle Scholar
  • 29 Golino P, Ravera A, Ragni M. et al. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes. Circulation 2003; 108: 2864-9.
    CrossrefPubMedGoogle Scholar
  • 30 Morange PE, Simon C, Alessi MC. et al. Endothelial cell markers and risk of coronary heart disease. Circulation 2004; 109: 1343-8.
    CrossrefPubMedGoogle Scholar
  • 31 Amini-Nekoo A, Futers ST, Moia M. et al. Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis. Br J Haematol 2001; 13: 537-43.
    PubMedGoogle Scholar
  • 32 Kleesiek K, Schmidt M, Götting C. et al. The 536C_h transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis. Thromb Haemost 1999; 82: 1-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Ehrenforth S, Junker R, Koch HG. et al. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr 1999; 158: S97-S104.
    CrossrefPubMedGoogle Scholar
  • 34 Dix D, Andrew M, Marzinotto V. et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136: 439-45.
    CrossrefPubMedGoogle Scholar
  • 35 Kijowski R, Hoppensteadt D, Walenga J. et al. Role of tissue factor pathway inhibitor in post surgical deep venous thrombosis prophylaxis in patients treated with low molecular weight heparin. Thromb Res 1994; 74: 53-64.
    CrossrefPubMedGoogle Scholar
  • 36 Hansen JB, Sanset PM, Huseby KR. et al. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol 1998; 101: 638-46.
    CrossrefPubMedGoogle Scholar
  • 37 Gori AM, Pepe G, Attanasio M. et al. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 1999; 81: 589-93.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Gerotziafas GT, Zafiropoulos A, van Dreden P. et al. Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina. Br J Haematol 2003; 120: 611-7.
    CrossrefPubMedGoogle Scholar
  • 39 Alban S, Gastpar R. Plasma Levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 2001; 85: 824-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Chouhan VD, Comerota AJ, Sun L. et al. Inhibition of tissue factor pathway during intermittent pneumatic compression: A possible mechanism for antithrombotic effect. Arterioscler Thromb Vasc Biol 1999; 19: 2812-7.
    CrossrefPubMedGoogle Scholar